Core Viewpoint - DexCom, Inc. has faced significant stock price decline following the announcement of its second quarter financial results for fiscal 2024 and a reduction in revenue guidance for the full fiscal year 2024, attributed to unmet strategic initiatives [2][3] Group 1: Financial Performance - On July 25, 2024, DexCom announced its second quarter financial results and lowered its revenue guidance for the full fiscal year 2024 [2] - The company's stock price dropped from $107.85 per share on July 25, 2024, to $64.00 per share on July 26, 2024, marking a decline of approximately 40.66% in one day [2] Group 2: Legal Action - Shareholders who purchased shares of DexCom during the class period from January 8, 2024, to July 25, 2024, are encouraged to contact the Gross Law Firm regarding potential lead plaintiff appointment [1][2] - The deadline for shareholders to register for the class action is October 21, 2024, and there is no cost or obligation to participate [3] Group 3: Company Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [4]

DexCom, Inc. (DXCM) is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust second-quarter 2024 performance, along with a series of favorable coverage decisions, is expected to contribute further. However, risks related to stiff competition persist.This Zacks Rank #3 (Hold) company’s shares have lost 46.8% year to date against the industry’s 9.9% growth. The S&P 500 Index has increased 21.1% in the same time frame.DXCM, a renowned medical device company and provide ...

DexCom Stock Performance and Market Position - DexCom stock is down by about 53% from its peak in April, despite starting the year with healthy gains [1] - The company markets one of the world's most popular continuous glucose monitors (CGM), which transmit data to smartphones or Apple Watches [1] - DexCom's stock fell by about 40% in July after management lowered its sales guidance, with Q3 sales growth expected to be only 1% to 3% year over year [2] - Full-year revenue expectations were revised down to $4 billion to $4.05 billion, from a previous range of $4.2 billion to $4.35 billion [2] Competitive Landscape - Abbott Laboratories, DexCom's lead competitor, did not issue a similar sales slowdown warning, raising investor concerns [2] - Abbott's FreeStyle Libre CGM sales grew 18.4% year over year in Q2 to $1.6 billion, about 60% more than DexCom's CGM revenue in the same period [3] - Medtronic, another major player, received FDA approval for its first disposable all-in-one CGM in August, intensifying competition [6] - Abbott and Medtronic announced a collaboration combining Abbott's CGM technology with Medtronic's insulin delivery system, potentially strengthening Abbott's market position [7] Market Opportunity and Product Innovation - DexCom's addressable market is large, with 29.4 million diagnosed diabetic adults in the U.S. and an estimated 8.7 million undiagnosed cases [4] - Approximately 38% of U.S. adults have prediabetes, creating additional demand for glucose monitoring [4] - DexCom launched Stelo, an over-the-counter CGM for non-insulin users, in August to tap into the growing market of health-conscious individuals [4] Challenges and Risks - DexCom's forward price-to-earnings ratio of 39.8 is high, suggesting the stock could fall further if the Q3 sales slowdown persists [5] - Eli Lilly's tirzepatide study showed a 94% reduction in the risk of progression to type 2 diabetes, potentially shrinking DexCom's addressable market [6] - DexCom's stock is not considered a bargain at its current valuation, and investors may need to wait for a return to previous growth rates [8]

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. due to significant stock price decline following the company's lowered sales guidance and operational issues [1][3] Financial Performance - On July 25, 2024, DexCom lowered its full year 2024 sales guidance to between $4 billion and $4.05 billion, a reduction of approximately $300 million from the previous guidance of $4.20 billion to $4.35 billion [2] - The company reported a "new patient shortfall" of 70,000 patients attributed to a "sales force disruption" and loss of market share in the Durable Medical Equipment channel [2] Stock Market Reaction - Following the announcement of the lowered guidance, DexCom's stock price fell by $43.85 per share, over 40%, closing at $64 per share on July 26, 2024 [3] Allegations in Lawsuit - The lawsuit alleges that during the class period, DexCom provided overly positive statements while concealing material adverse facts about its salesforce capabilities, leading to artificially inflated stock prices [3]

NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and ...

SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM), alleging that the medical device company made misleading statements about its financial performance and growth prospects. Hagens Berman urges DexCom investors who suffered substantial losses to submit your losses now. Class Period: Jan. 8, 2024 – July 25, 2024Lead Plaintiff Deadline: Oct. 21, 2024Visit: www.hbsslaw.com/investor-fraud/DXCM Contact the Firm Now: DXCM@hbsslaw.com       ...

NEW YORK, Sept. 30, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM).Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form/?id=105579&from=4 CLASS PERIOD: January 8, 2024 to July 25, ...

Core Points - A securities class action lawsuit has been filed against DexCom, Inc. for alleged misleading statements and failure to disclose critical business challenges during the Class Period from January 8, 2024, to July 25, 2024 [1][2] - The lawsuit claims that DexCom's optimistic communications regarding growth and margins were unfounded, and that the company struggled to maintain successful distribution channels [2] - Investors have until October 21, 2024, to seek appointment as lead plaintiff in the class action, which allows them to represent the interests of all affected investors [3] Allegations Against DexCom - The complaint alleges that DexCom made materially false and misleading statements about its business operations and prospects [2] - Specific claims include that the company's growth expectations were overly optimistic and that it faced difficulties in retaining distribution channels [2] Legal Process for Investors - Investors can choose to become lead plaintiffs or remain absent class members, with the lead plaintiff responsible for directing the litigation [3] - The lead plaintiff is typically the investor or group of investors with the largest financial interest in the case [3] Firm Information - Kessler Topaz Meltzer & Check, LLP is handling the class action and has a history of recovering billions for victims of corporate misconduct [5] - The firm encourages affected DexCom investors to contact them for more information [4]

NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) an ...

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. for allegedly making misleading statements regarding its financial performance and growth prospects [1][2]. Group 1: Lawsuit Details - The lawsuit, titled Alonzo v. DexCom, Inc., represents investors who purchased DexCom securities between January 8, 2024, and July 25, 2024 [2]. - Plaintiffs claim that DexCom and its executives violated federal securities laws by providing false and misleading information about the company's growth, earnings potential, and margins [2]. - The lawsuit alleges that DexCom overstated its ability to attract new customers and maintain existing distribution channels [2]. Group 2: Financial Performance - On July 25, 2024, DexCom announced disappointing financial results for Q2 2024 and lowered its revenue guidance for the full year, attributing the shortfall to unmet expectations from several key strategic initiatives [2]. - Following the announcement, DexCom's stock price fell by nearly 41% [3]. Group 3: Investigation and Whistleblower Information - Hagens Berman, a prominent shareholder rights firm, has initiated an investigation into potential violations of U.S. securities laws by DexCom [3]. - The investigation aims to determine whether DexCom misled the public about the risks associated with its strategic decisions [3]. - Whistleblowers with non-public information regarding DexCom are encouraged to assist in the investigation, with potential rewards under the SEC Whistleblower program [3].